RxDoctor Payments Data

Andrew Tegeder, MD

Dermatology · Missoula, MTNPI 1376835769

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 38.8% of the total.

$3,295in general payments, 2019–2025

Across 223 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$451
  • Johnson & Johnson$414
  • Prugen, Inc. Pharmaceuticals$215
  • Sanofi$182
  • E.r. Squibb & Sons, L.L.C.$177
  • plus $577 from 11 others
$364,497in research payments, 2019–2025

Across 52 payments — averaging $7009.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$141K
  • Incyte Corporation$103K
  • Sanofi US Services Inc.$91K
  • Sanofi Pasteur Inc.$16K
  • Sun Pharmaceutical Industries Inc.$13K

What the payments were for

  • Food & beverage$3,09694%
  • Education$1996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,295 in reported general payments places this provider in the 70th percentile of 46 dermatology providers in Montana.

See all dermatology providers in Montana

Medicare billing

Part B allowed, 2024
$348,158
Medicare patients
1,318
Services billed
6,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa18$378,463
Enbrel SureclickEtanercept15$115,731
RinvoqUpadacitinib15$96,962
Cosentyx Sensoready (2 Pens)Secukinumab13$96,321
Taltz AutoinjectorIxekizumab11$74,853
Clobetasol Propionate136$5,933
MethotrexateMethotrexate Sodium44$1,618
Hydroxychloroquine Sulfate12$1,595
Metronidazole20$1,484
Doxycycline Hyclate28$1,480
Ketoconazole92$1,329
Doxycycline Monohydrate29$1,160
Tretinoin13$949
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc60$879
Triamcinolone Acetonide82$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,278$96,96215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 46 dermatology providers in Montana.

Other dermatology in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →